A detailed history of Bank Of Montreal transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 52,341 shares of VERV stock, worth $260,658. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,341
Previous 54,778 4.45%
Holding current value
$260,658
Previous $727,000 64.92%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.76 - $12.79 $11,600 - $31,169
-2,437 Reduced 4.45%
52,341 $255,000
Q1 2024

May 13, 2024

SELL
$10.81 - $17.96 $417,395 - $693,471
-38,612 Reduced 41.34%
54,778 $727,000
Q4 2023

Feb 08, 2024

BUY
$8.84 - $18.7 $184,420 - $390,119
20,862 Added 28.76%
93,390 $1.3 Million
Q3 2023

Nov 01, 2023

BUY
$11.42 - $20.82 $828,269 - $1.51 Million
72,528 New
72,528 $961,000
Q1 2023

Jun 13, 2024

SELL
$14.3 - $24.01 $450,821 - $756,939
-31,526 Reduced 57.55%
23,252 $335,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $299M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.